检索结果-南通市图书馆

Mechanism of Mingjing Granules in Treating wet age-related macular degeneration Based on Network Pharmacology and Experimental Verification

引用

World Journal of Traditional Chinese Medicine 2024年第1期10卷 22-32页

作者： Xiao-Yu Li Li-Na Liang Wei-Jun Zhang Yun Gao Qiang Chen Eye Function Laboratory Eye HospitalChina Academy of Chinese Medical SciencesBeijingChina China Evidence-Based Medicine Center for Traditional Chinese Medicine BeijingChina Center for East-West Medicine UCLA David Geffen School of MedicineLos AngelesCAUSA

Objective:To analyze the potential mechanism of Mingjing granules in the treatment of wet age-related macular degeneration(wAMD)based on the research methods of network pharmacology and molecular docking approach and to provide a new reference for the currently limited treatment of *** and Methods:We searched TCMSP,GeneCards,OMIM,PharmGkb,TTD,and DrugBank database to screen the main active ingredients of Mingjing granules and their therapeutic targets of *** network of active components and targets was constructed using Cytoscape3.6.1 software,which was also used for the topological analysis of target *** network of Protein-Protein Interactions(PPI)was mapped using the String *** also used R language to do the Gene Ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway for additional *** docking studies were finished by Chemoffice,Autodock,and ***,the efficacy of the Mingjing granules was examined in animal experiments,in which we used enzyme-linked immunosorbent assay to the contents of vascular endothelial growth factor(VEGF)and matrix metalloproteinase-9(MMP-9)levels in peripheral ***:Active compounds,including quercetin,lignocaine,and kaempferol,were *** network analysis showed that tumor necrosis factor(TNF),MMP-9,epidermal growth factor(EGF),prostaglandin-endoperoxide synthase 2(PTGS2),and caspase-3(CASP3)were related to both Mingjing granules and *** and KEGG pathway analysis showed that these targets were mainly involving lipids and atherosclerosis,TNF,and interleukin-17(IL-17)signaling *** studies suggested that quercetin and luteolin can fit in the binding pocket of four target proteins(CASP3,EGF,PTGS2,and TNF).In the vivo experiment,the Mingjing granules were found to be effective on the expression of VEGF and MMP-9 in peripheral ***:This study initially reveals the multi-constituent,multi-target,and multi-pathway mechanism of action of Ming

关键词： Experimental verification Mingjing granules molecular docking network pharmacology wet age-related macular degeneration

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Efficacy and safety of intravitreal HLX04-O,an anti-VEGF monoclonal antibody,for the treatment of wet age-related macular degeneration

引用

International Journal of Ophthalmology(English edition) 2022年第9期15卷 1549-1553页

作者： Zhen Zhang Ying Wu Ya-Li Lyu Meng-Qi Chang Qiu-Jin Xu Yi-Ming Liu Wen-Ying Kang Qing-Yu Wang Chuan-Ling Li Department of Ophthalmology Xuzhou Central HospitalXuzhou 221009Jiangsu ProvinceChina Department of Ophthalmology Eye&ENT Hospital of Fudan UniversityShanghai 200031China Shanghai Henlius Biotech Inc.Shanghai 200233China Department of Phase 1 Clinical Trial Xuzhou Central HospitalXuzhou 221009Jiangsu ProvinceChina

·AIM:To evaluate the efficacy and safety of HLX04-O,an investigational ophthalmic formulation of HLX04(bevacizumab biosimilar)for intravitreal injection,as a treatment for wet age-related macular degeneration(wAMD)in a phase 1/2 clinical trial(NCT04993352).·METHODS:Eligible patients with wAMD were enrolled to receive HLX04-O intravitreal injections at a dose of1.25 mg/0.05 mL every four *** and adverse events were evaluated every month during study visits.·RESULTS:A 76-year-old male with wAMD in his left eye participated in the trial and completed six cycles of HLX04-O intravitreal *** were observed in macular center point thickness(baseline vs last study visit,437 vs 255μm)and best-corrected visual acuity letter score(baseline vs last study visit,36 vs 77)of the affected eye,which indicated an improvement in wAMD over *** adverse events were reported by the data cutoff date.·CONCLUSION:HLX04-O at 1.25 mg/0.05 mL every four weeks is well tolerated in this patient,demonstrating promising safety and efficacy in wAMD *** studies are required to confirm the outcomes.

关键词： wet age-related macular degeneration anti-vascular endothelial growth factor bevacizumab HLX04 HLX04-O

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Single-site Baseline and Short-term Outcomes of Clinical Characteristics and Life Quality Evaluation of Chinese wet age-related macular degeneration Patients in Routine Clinical Practice

引用

Chinese Medical Journal 2015年第9期128卷 1154-1159页

作者： Li-Li Wang Wen-Jia Liu Hai-Yun Liu Xun Xu Department of Ophthalmology Shanghai First People@s Hospital Shanghai 200080 China

Background：age-related macular degeneration （AMD） is the leading cause of irreversible vision loss among the older *** China,treatment of age-related ocular diseases is becoming a priority in eye care *** study was to investigate the clinical characteristics and quality of life of Chinese patients with wet AMD and current treatment types,to evaluate short-term gains in different treatments,and to investigate associations between visual function and vision-related quality of life （VRQoL）.Methods：A prospective,observational,noninterventional study was *** data were collected from patients with clinical diagnoses of wet AMD before clinical assessments at *** was measured with the Chinese version of the National Eye Institute Visual Function Questionnaire-25 （NEI VFQ-25）.Correlations of the NEI VFQ-25 subscale scores with best-corrected visual acuity （BCVA） and between-group differences were ***：A total of 80 wet AMD patients were enrolled,with the mean age of 68.40 *** one-quarter ofwetAMD patients received intravitreal （IVT） ranibizumab treatment,and 67％ of them were treated on apro re nata *** visual acuity of patients treated with IVT ranibizumab at month 3 after treatment was significantly increased,whereas patients treated with traditional Chinese medicine achieved no significant ***＇s α for the NEI VFQ-25 subscales ranged from 0.697 to *** subscale and overall composite scores were moderately correlated with the BCVA of the better-seeing *** differences in the overall NEI VFQ-25 scores and other subscales were observed between patients with BCVA in the better-seeing eye of less than 50 letters and the ***：Patients treated with IVT ranibizumab experienced better vision improvement at short-term *** Chinese version of the NEI VFQ-25 is a valid and reliable tool for assessing the VRQoL of Chinese wet AMD patients.

关键词： Chinese Version of National Eye Institute Visual Function Questionnaire-25 Ranibizumab Vision-related Quality of Life wet age-related macular degeneration

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

One-year outcomes of resveratrol supplement with aflibercept versus aflibercept monotherapy in wet agerelated macular degeneration

引用

International Journal of Ophthalmology(English edition) 2023年第9期16卷 1496-1502页

作者： Ioannis Datseris Nikolaos Bouratzis Charalambos Kotronis Iordanis Datseris Malvina-Efthimia Tzanidaki Alexandros Rouvas Nikolaos Gouliopoulos Ophthalmological Institute OMMA Athens 11525Greece Specialized Eye Hospital“Ophthalmiatreion”Athinon Athens 10672Greece 2^(nd)Department of Ophthalmology Medical School of University of Athens“Attikon”University HospitalAthens 12462Greece

AIM:To determine the one-year outcomes of resveratrol oral supplement in patients suffering from wet age-related macular degeneration(AMD).METHODS:Fifty naïve and previously untreated patients suffering from wet AMD,were randomly assigned in two subgroups of 25 patients *** the participants were treated with 3 monthly intravitreal injections of 2.0 mg aflibercept(IAIs)followed by injections“according to need”,while in one group the patients also received daily two tablets of resveratrol oral *** to treatment initiation,a complete ophthalmological examination,including best corrected visual acuity(BCVA)and contrast sensitivity evaluation,optical coherence tomography(OCT)scans,fundus autofluorescence(FAF),fluorescein angiography,indocyanine green angiography,and OCT angiography(OCTA),was performed to every participant,while all of them completed the Hospital Anxiety and Depression Scale(HADS)questionnaire,in order to assess their quality of life(QoL)*** patients were assessed monthly for 1y with FAF,and OCT or OCTA;the main endpoints were the number IAIs,the changes in BCVA,in contrast sensitivity,and in patients’QoL ***:No significant differences were present between the groups regarding the baseline demographic and clinical *** the 12-month period,a similar number of IAIs was applied in both groups(4.52±1.00 vs 4.28±0.90,P=0.38),while the rest of the clinical data also did not differ significantly after the completion of the study ***,for HADS Depression(11.88±2.51 vs 8.28±1.54,P<0.001)and HADS Anxiety(11.92±2.52 vs 7.76±1.51,P<0.001)questionnaires values,the score was significantly better in patients who received resveratrol ***,a statistically significant difference was detected in the mean change from baseline values of contrast sensitivity(0.17±0.19 vs 0.35±0.24,P=0.005),HADS Depression(0.08±1.38 vs-3.88±1.48,P<0.001),and HADS Anxiety(0.36±1.98 vs-5.12±2.70,P<0.001)scores,in favour of the pati

关键词： wet age-related macular degeneration resveratrol aflibercept Hospital Anxiety and Depression Scale contrast sensitivity

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Tissue factor with age-related macular degeneration

引用

International Journal of Ophthalmology(English edition) 2012年第5期5卷 609-613页

作者： Guan-Feng Wang Xiu-Lan Zou Department of Ophthalmology Guangzhou General Hospital of Guangzhou Military Command Guangzhou 510010 Guangdong Province China Jinan University Guangzhou 510630 Guangdong Province China

wet age-related macular degeneration which incidence increases year by year is a blinding eye disease, but current clinical methods of treatment on this disease are limited and the outcome is not ideal. Recent studies have found abnormally high expression of tissue factors which are targets for the treatment of wet age-related macular degeneration to achieve a certain effect in the choroidal neovascularization. related literatures are reviewed as following.

关键词： wet age-related macular degeneration choroidal neovascularzation tissue factor photodynamic therapy immunotherapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Impact of switching from ranibizumab to aflibercept on the number of intravitreous injection and follow up visit in wet AMD:results of real life ELU study

引用

International Journal of Ophthalmology(English edition) 2020年第2期13卷 252-256页

作者： Frederic Queguiner Kristina Bezirganyan Jean Christophe Courjaret Laurence Curel Guillaume Penaranda Maud Righini Chossegros Ophthalmology and Clinical Research Departments Hopital Saint JosephMarseille F-13008France Biostatistics Department Alphabio LaboratoryMarseille F-13003France

●AIM:To study if one of the two molecules could lead to a lower number of follow up visits and intra-vitreous injection(IVI)with the same efficacy.●METHODS:ELU(or"elected"in French)study is a retrospective study conducted in real life in patients presenting suboptimal response after ranibizumab IVI(phase 1)and secondary switched to aflibercept(phase 2).The number of follow up visits and IVI were compared in both *** acuity(VA)evolution and"switching"reasons were secondary analyzed.●RESULTS:We retrospectively included data of 33 patients(38 eyes)with age-related macular degeneration(AMD;mean age:77±7.7 y).The number of monthly follow up visits[median(Q1;Q3)]:was significantly lower with aflibercept(phase 2),respectively 1.0(0.81;1.49)visits in phase 1,versus 0.79(0.67;0.86)visits in phase *** median number of monthly IVI also significantly decreased in phase 2,respectively 0.67(0.55;0.90)IVI in phase 1,versus 0.55(0.45;0.67)IVI in phase *** mean VA evolution(VA final-VA initial)was similar in both phases,(P>0.05).Whatever the reason for"switching"(loss of efficacy,tachyphylaxis,tolerance problems),there was no incidence on VA evolution over the time.●CONCLUSION:Our results show that switching from ranibizumab to aflibercept in"suboptimal"patients significantly reduce the number of follow up visits and IVI,with a comparable *** decrease in visit number could improve patients’quality of life and reduce surgical risk by reducing the number of injections.

关键词： wet age-related macular degeneration anti-VEGF aflibercept ranibizumab follow up visit intravitreal injection visual acuity

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：